Screener / SEC EDGAR /CIK 0000939767 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Exelixis, Inc. EXEL

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 2 of 2 range targets
Below the range 0 below the last range given

The numbers EXEL said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $2.52B to $2.62B release Feb 10, 2026
Kept $2.52B to $2.62B release May 5, 2026
Lowered $2.50B to $2.55B release Aug 5, 2026
Kept $2.50B to $2.55B release Oct 29, 2026
– Not reported yet
The company's words
2026 Financial Guidance … Total revenues $2.525 billion - $2.625 billion release Feb 10, 2026
2026 Financial Guidance … Total revenues $2.525 billion - $2.625 billion release May 5, 2026
Current Guidance Previous Guidance (provided on August 5, (provided on January … Total revenues $2.500 billion - $2.550 billion release Aug 5, 2026
Current Guidance Previous Guidance (provided on October (provided on August 5, … Total revenues $2.500 billion - $2.550 billion release Oct 29, 2026
Revenue
Fiscal 2025 (ended Jan 2, 2026)
Given $2.15B to $2.25B release Feb 11, 2025
Raised $2.25B to $2.35B release May 13, 2025
Kept $2.25B to $2.35B release Jul 28, 2025
Raised $2.30B to $2.35B release Nov 4, 2025
$2.32B
10-K filed 2026-02-10
Within the range
The company's words
The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' supplemental New Drug Application (sNDA) for this proposed indication, with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. … Total revenues $2.15 billion - $2.25 billion release Feb 11, 2025
Current Guidance Previous Guidance (provided on May 13, (provided on January … Total revenues $2.25 billion - $2.35 billion release May 13, 2025
Exelixis is maintaining the previously provided financial guidance for fiscal year 2025. … Total revenues $2.25 billion - $2.35 billion release Jul 28, 2025
Current Guidance Previous Guidance (provided on November (provided on May 13, … Total revenues $2.30 billion - $2.35 billion release Nov 4, 2025
Revenue
Fiscal 2024 (ended Jan 3, 2025)
Given $1.65B to $1.75B release Jan 8, 2024
Raised $1.82B to $1.93B release Feb 6, 2024
Kept $1.82B to $1.93B release Apr 30, 2024
Raised $1.98B to $2.08B release Aug 6, 2024
Raised $2.15B to $2.20B release Oct 29, 2024
$2.17B
10-K filed 2025-02-11
Within the range
The company's words
– Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; release Jan 8, 2024
Exelixis is maintaining the previously provided financial guidance for fiscal year 2024 (1) : … Total revenues $1.825 billion - $1.925 billion release Feb 6, 2024
Exelixis is maintaining the previously provided financial guidance for fiscal year 2024 (1) : … Total revenues $1.825 billion - $1.925 billion release Apr 30, 2024
Exelixis is providing the following updated financial guidance for fiscal year 2024 (1) : … Total revenues $1.975 billion - $2.075 billion release Aug 6, 2024
Current Guidance Previous Guidance (provided on October (provided on August 6, … Total revenues $2.150 billion - $2.200 billion release Oct 29, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.